CGIM
MDGL icon

Cannon Global Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cannon Global Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,000
Closed -$1.05M – 76
2026
Q1 		$1.05M Buy
+2,000
New +$956K 2.04% 10

Other funds holding MDGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EAM
EULAV Asset Management Sarasota, Florida $3.13B AUM 23.04% 1-Year Est. Return

Cannon Global Investment Management's MDGL Position: Q2 2026 in Review

Cannon Global Investment Management increased its Madrigal Pharmaceuticals (MDGL) stake by 88% in Q2 2026, buying an estimated $359K and bringing the position to 1,500 shares worth $805K. The position accounts for 2.28% of the portfolio, ranked #15.

Cannon Global Investment Management first reported a position in MDGL in Q1 2025 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Cannon Global Investment Management held 1,500 shares of Madrigal Pharmaceuticals worth $805K as of Q2 2026.
  • Cannon Global Investment Management bought 700 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $359K.
  • Madrigal Pharmaceuticals made up 2.28% of Cannon Global Investment Management's portfolio in Q2 2026, its #15 holding.
  • Cannon Global Investment Management first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Cannon Global Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.